Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director | September 03, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 328,436 |
Ending reported balance
After 2026-09-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-03 · Sale · Disposed 7,012 · Balance 341,424 F1: This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-03 · Sale · Disposed 6,814 · Balance 334,610 F2: This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-03 · Sale · Disposed 6,174 · Balance 328,436 F3: This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F2: This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2021 Filed Apr 19, 2021 17:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 926 | $192.85 | $178,577.62 |
DisclosureSEC source: 0001209191-21-027322 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,784 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $192.40 to $193.20. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 17:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 681 | $191.85 | $130,649.65 |
DisclosureSEC source: 0001209191-21-027322 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,710 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $191.40 to $192.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 17:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,500 | $190.70 | $286,056.15 |
DisclosureSEC source: 0001209191-21-027322 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,391 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $190.40 to $191.20. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 17:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $189.97 | $208,970.52 |
DisclosureSEC source: 0001209191-21-027322 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,891 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $189.40 to $190.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 17:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $185.90 | $111,541.98 |
DisclosureSEC source: 0001209191-21-024713 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $185.81 to $186.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 17:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,487 | $185.21 | $645,844.36 |
DisclosureSEC source: 0001209191-21-024713 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,591 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $184.71 to $185.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 17:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,272 | $184.22 | $418,538.75 |
DisclosureSEC source: 0001209191-21-024713 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,078 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $183.70 to $184.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 17:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $183.19 | $128,233.00 |
DisclosureSEC source: 0001209191-21-024713 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,350 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $182.69 to $183.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 17:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $181.83 | $36,365.00 |
DisclosureSEC source: 0001209191-21-024713 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,050 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $181.56 to $182.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 17:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 241 | $180.27 | $43,446.18 |
DisclosureSEC source: 0001209191-21-024713 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,250 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $179.98 to $180.69. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $174.50 | $69,798.00 |
DisclosureSEC source: 0001209191-21-021951 · doc4.xml · nonDerivative · entry 10 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · price: This transaction was executed in multiple trades at prices ranging from $174.18 to $174.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $173.28 | $69,313.00 |
DisclosureSEC source: 0001209191-21-021951 · doc4.xml · nonDerivative · entry 9 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,891 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · price: This transaction was executed in multiple trades at prices ranging from $172.90 to $173.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,266 | $172.29 | $218,114.08 |
DisclosureSEC source: 0001209191-21-021951 · doc4.xml · nonDerivative · entry 8 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,291 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $171.79 to $172.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $171.27 | $85,636.50 |
DisclosureSEC source: 0001209191-21-021951 · doc4.xml · nonDerivative · entry 7 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,557 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $170.77 to $171.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 813 | $170.09 | $138,280.65 |
DisclosureSEC source: 0001209191-21-021951 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,057 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $169.76 to $170.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $169.27 | $186,198.98 |
DisclosureSEC source: 0001209191-21-021951 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,870 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $168.71 to $169.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 920 | $167.98 | $154,539.76 |
DisclosureSEC source: 0001209191-21-021951 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,970 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $167.59 to $168.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 601 | $166.80 | $100,247.28 |
DisclosureSEC source: 0001209191-21-021951 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,890 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $166.42 to $167.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $165.80 | $132,637.04 |
DisclosureSEC source: 0001209191-21-021951 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $165.38 to $166.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 21:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $164.88 | $115,416.00 |
DisclosureSEC source: 0001209191-21-021951 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,291 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $164.38 to $165.32. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $186.85 | $37,369.00 |
DisclosureSEC source: 0001209191-21-017000 · doc4.xml · nonDerivative · entry 8 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $186.79 to $186.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,883 | $186.14 | $536,649.40 |
DisclosureSEC source: 0001209191-21-017000 · doc4.xml · nonDerivative · entry 7 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,191 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $185.73 to $186.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $184.93 | $73,973.00 |
DisclosureSEC source: 0001209191-21-017000 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,074 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $184.70 to $185.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $183.94 | $110,365.98 |
DisclosureSEC source: 0001209191-21-017000 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,474 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $183.60 to $184.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $182.02 | $127,410.99 |
DisclosureSEC source: 0001209191-21-017000 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,074 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $181.61 to $182.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $180.95 | $90,473.00 |
DisclosureSEC source: 0001209191-21-017000 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,774 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $180.56 to $181.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,317 | $179.75 | $236,727.85 |
DisclosureSEC source: 0001209191-21-017000 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,274 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $179.25 to $180.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 900 | $178.80 | $160,918.02 |
DisclosureSEC source: 0001209191-21-017000 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,591 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $178.20 to $179.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $199.78 | $59,934.99 |
DisclosureSEC source: 0001209191-21-012038 · doc4.xml · nonDerivative · entry 9 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · price: This transaction was executed in multiple trades at prices ranging from $199.46 to $200.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 233 | $198.08 | $46,152.57 |
DisclosureSEC source: 0001209191-21-012038 · doc4.xml · nonDerivative · entry 8 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,791 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $197.89 to $198.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 633 | $197.36 | $124,929.45 |
DisclosureSEC source: 0001209191-21-012038 · doc4.xml · nonDerivative · entry 7 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,024 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $196.86 to $197.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $195.43 | $156,345.12 |
DisclosureSEC source: 0001209191-21-012038 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,657 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $195.24 to $195.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $194.60 | $116,760.00 |
DisclosureSEC source: 0001209191-21-012038 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,457 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $194.15 to $195.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 451 | $192.61 | $86,868.51 |
DisclosureSEC source: 0001209191-21-012038 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,057 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $192.18 to $192.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,683 | $191.63 | $514,140.34 |
DisclosureSEC source: 0001209191-21-012038 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,508 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $191.11 to $192.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,400 | $190.42 | $266,582.12 |
DisclosureSEC source: 0001209191-21-012038 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,191 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $190.05 to $190.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $189.51 | $75,802.44 |
DisclosureSEC source: 0001209191-21-012038 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,591 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $188.99 to $189.91. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $178.98 | $35,796.00 |
DisclosureSEC source: 0001209191-21-007564 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $178.97 to $178.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $178.16 | $53,447.01 |
DisclosureSEC source: 0001209191-21-007564 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,191 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $177.90 to $178.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,202 | $177.23 | $213,035.15 |
DisclosureSEC source: 0001209191-21-007564 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $176.81 to $177.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,304 | $176.14 | $405,821.03 |
DisclosureSEC source: 0001209191-21-007564 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,693 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $175.78 to $176.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,094 | $175.38 | $542,624.48 |
DisclosureSEC source: 0001209191-21-007564 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,997 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $174.77 to $175.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $174.14 | $69,656.00 |
DisclosureSEC source: 0001209191-21-007564 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,091 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $173.50 to $174.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 376 | $182.78 | $68,726.07 |
DisclosureSEC source: 0001209191-21-004663 · doc4.xml · nonDerivative · entry 7 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $182.55 to $182.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 900 | $181.49 | $163,342.98 |
DisclosureSEC source: 0001209191-21-004663 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,867 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $180.97 to $181.81. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,206 | $180.27 | $217,406.46 |
DisclosureSEC source: 0001209191-21-004663 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,767 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $179.96 to $180.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,608 | $179.28 | $288,285.30 |
DisclosureSEC source: 0001209191-21-004663 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,973 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $178.90 to $179.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,110 | $178.31 | $197,925.32 |
DisclosureSEC source: 0001209191-21-004663 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,581 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $177.80 to $178.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 900 | $176.57 | $158,910.03 |
DisclosureSEC source: 0001209191-21-004663 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,691 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $176.20 to $177.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 16:28 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,400 | $175.79 | $246,103.06 |
DisclosureSEC source: 0001209191-21-004663 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,591 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $175.20 to $176.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.